Praxis Precision Medicines anticipates four pivotal clinical trial readouts in 2025, positioning the company for potential commercial launches between 2026 and 2028.
The FDA has granted Rare Pediatric Disease Designation (RPDD) to Praxis Precision Medicines' relutrigine for the treatment of Dravet syndrome, a severe form of epilepsy.
Praxis Precision Medicines is advancing relutrigine for developmental and epileptic encephalopathies (DEEs), showcasing robust Phase 2 data with improvements in motor seizures.